In contrast, RHBDL2 has been shown to delay cancer progression, with its upregulation being required for the spontaneous conversion of CD44−/CD24− breast cancer cells into CD44+/CD24− cancer stem cells in patient‐derived samples (Qiao et al. 2021). Here, RHBDL2 is linked to cancer.